Vaccines

A benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

Many families fell behind on vaccines during the pandemic, but a study finds most clinics are available to schedule make-up appointments.

A single injection of the Ad5-vectored COVID-19 vaccine induced specific immune responses to the spike glycoprotein at day 28.

The development of BNT162 is based on BioNTech’s mRNA platform; the vaccine will then be produced using Pfizer’s vaccine manufacturing capacities.

The European Commission has granted Marketing Authorization for a 2-dose Ebola vaccine regimen.

New recommendations are intended to aid biomedical firms in achieving licensure of a safe and effective vaccine.

While smallpox may not be in headlines today, the illness (treated with tecovirimat) remains a threat.

Dr. Luwy Musey, executive director in biologics, Merck Research Laboratories, discusses what clinicians need to know about the latest PCVs.

In a joint-interview, we discuss the PCV pipeline with Dr. Luwy Musey (of Merck & Co.) and Dr. Steven Pelton.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

Data were published using the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.

Infectious disease experts have recommended that stockpiles of several promising vaccine candidates be created as they enter late stage development.

Patrick Soon-Shiong, MD, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

As of June 1, there have been at least 6 cases of Ebola detected in Mbandaka, a port city with a population of more than 1.2 million people.

In all trial participants to date, the vaccine candidate led to seroconversion with binding antibody levels either at or above levels seen in convalescent sera.

Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts, a new study found.

What is the hopeful expectation of the new candidates, relative to previously developed vaccines?

Preventive medicine expert William Schaffner, MD, discusses what it will take for investigators to properly assess and manufacture a vaccine.

In a new phase 4 study, investigators found giving patients raxibacumab at the start of anthrax vaccine adsorbed administration does hurt the protective quality of the vaccine.

Moderna hopes to initiate phase 2 and late stage studies of its vaccine candidate, mRNA-1273, against COVID-19.

Flu burden for children can be reduced by improving adherence to a 2-dose series of flu vaccinations.

The attenuated virus in oral polio vaccines has developed the ability to evolve and spread to humans. Now, investigators have developed a new vaccine without the ability to make such changes.

Vaccination rates remain below recommended levels in many areas.

Disparate reimbursement policies disincentivize clinicians from vaccinating adults with lower incomes.

The authors of the review recommend the continued use of MMR vaccines on a mass scale.